Concepedia
Statistics
Publications
22
Citations
3K
H-Index
17
Active since
1983
Affiliations
Pfizer (United States)(Current)
Monsanto (United States)
Phenomenome Discoveries (Canada)
University of Central Florida
Vertex Pharmaceuticals (United States)
Gary DeCrescenzo is an author at Pfizer (United States) specializing in pharmacology, pharmacy, and medicinal chemistry.
Publications per year
1983–2020
Physiochemical drug properties associated with in vivo toxicological outcomes
Jason D. Hughes, Julian Blagg, David A. Price et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 973 citations
Pharmacy, Pharmacology, Toxicology +14
Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature
Steven Seaman, Zhongyu Zhu, Saurabh Saha et al. · Cancer Cell · 2017 · 447 citations
Medicine, Immunology, Oncology +14
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Ryan J. Sullivan, Jeffrey R. Infante, Filip Jankú et al. · Cancer Discovery · 2017 · 418 citations
Medicine, Oncology, Pharmacology +14
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Ursula A. Germann, Brinley F. Furey, William Markland et al. · Molecular Cancer Therapeutics · 2017 · 234 citations
Medicine, Oncology, Pharmacology +16
Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere
Daniel P. Getman, Gary DeCrescenzo, R. Heintz et al. · Journal of Medicinal Chemistry · 1993 · 179 citations · Full text
Pharmacy, Medicinal Chemistry, Pharmacology +9
1–5 of 22